TRUSCREEN GROUP LIMITED — Capital/Financing Update 2026

May 20, 2026

truscreen®
a world without cervical cancer
^{}[]

NZX/ASX Announcement

21 May 2026

Notice of Offer of Same Class Financial Products for Issue

1. Truscreen Group Limited (NZX/ASX: TRU) ("TRU" or "Company") today announced that it intends to undertake a capital raising, comprising:

a. a placement of up to NZ$1,000,000 (A$833,333) of newly issued ordinary shares in TRU ("Shares") to institutional and other select investors (the "Placement"), with the ability to accept oversubscriptions (at the Board's discretion and subject to Shareholder approval, if required);

b. a one (1) for five (5) renounceable rights issue of up to circa NZ$1.943 million (A$1.644 million) of newly issued Shares to TRU's eligible shareholders in New Zealand and Australia (being New Zealand and Australian resident shareholders, on the share register on the record date of Thursday, 28 May 2026) (the "Rights Issue"); and

c. Shares issued under the Placement will carry attaching options with an exercise price of NZ$0.014 (A$0.012) and an exercise period of 24 months from the date of issue of the initial Share. The options are being offered at a ratio of one (1) option for every two (2) Shares subscribed for and issued under the Placement (the "Placement Options").

The Company also intends to issue up to 30,000,000 options to the joint lead managers of the Placement (SP Corporate Advisory Pty Ltd and Erity Capital Pty Ltd) in consideration for services provided, subject to Shareholder approval (together with the Placement Options, the "Options"),

(the "Offer").

1. The Placement opens today, 21 May 2026. The Rights Issue will open on Friday, 29 May 2026.

2. The Company today also announced a variation offer in respect of the 204,741,031 unlisted options currently on issue (the "Existing Options"). The Existing Options were issued on 17 July 2025 as part of a capital raising announced by the Company on 29 May 2025. All Existing Options have an exercise price of

truscreen
TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
a world without cervical cancer
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00 00

---

truscreen®
a world without cervical cancer

NZ$0.022 (A$0.02) per option and currently expire on 17 July 2026. The Company is offering to extend the expiry date of all Existing Options to 17 July 2027 ("Options Extension"). All other terms and conditions of the Existing Options, including the exercise price of NZ$0.022 (A$0.02) per option, will remain unchanged.

1. The Offer and the Options Extension are being made in New Zealand in reliance upon the exclusions in clause 19(1) and 19(1A) of schedule 1 to the Financial Markets Conduct Act 2013 ("Act"). This notice is provided under subclause 20(1)(a) of schedule 8 to the Financial Markets Conduct Regulations 2014 ("Regulations").

2. TRU advises that, as at the date of this Cleansing Notice:

a. TRU is in compliance with the continuous disclosure obligations that apply to it in relation to TRU’s quoted financial products;
b. TRU is in compliance with its “financial reporting obligations” (within the meaning set out in clause 20(5) of Schedule 8 of the Regulations); and
c. there is no information that is “excluded information” (within the meaning set out in clause 20(5) of Schedule 8 of the Regulations).

1. Neither the Offer nor the Options Extension is expected to have any material effect or consequences on the control of TRU within the meaning set out in clause 48 of Schedule 1 of the Act.

2. The Offer is being made in Australia:

a. in respect of the Placement and the Options, in reliance upon the exemptions relating to “sophisticated investors” and “professional investors” under section 708 of the Corporations Act 2001 (Cth) ("Corporations Act");
b. in respect of the Rights Issue, pursuant to section 708AA of the Corporations Act (as notionally modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2026/98 and ASIC Instrument 23-0122); and
c. in respect of the offer of shortfall shares from the Rights Issue under a shortfall bookbuild to investors that are not eligible shareholders, in reliance upon the exemptions relating to “sophisticated investors” and “professional investors” under section 708 of the Corporations Act.

1. TRU advises that:

truscreen
TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
a world without cervical cancer
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00 00 00

---

truscreen®
a world without cervical cancer

a. TRU will offer shares under the Offer without disclosure to investors under Part 6D.2 of the Corporations Act;
b. this Cleansing Notice is being given under sections 708AA(2)(f) and 708A(12J) (as notionally inserted by ASIC Instrument 23-0122) of the Corporations Act; and
c. as at the date of this Cleansing Notice, TRU has complied with its obligations under Rule 1.15.2 of the ASX Listing Rules.

1. The Options Extension is being made in Australia pursuant to a “transaction specific” prospectus under section 713 of the Corporations Act (as notionally modified by ASIC Instrument 25-0323).

On behalf of the Board,

Guy Robertson
Chief Financial Officer
Truscreen Group Limited

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Jack Zhang
Media & Investor Relations
jack@sparkplus.org

truscreen
a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国际开放政策研究

---

truscreen®
a world without cervical cancer

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”.

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.

truscreen®
a world without cervical cancer

TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 13485
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
00 00 00 00 00 00 00

---

truscreen®
a world without cervical cancer
^{}[]

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. DALTONbio’s exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.

^{}[]
truscreen®
a world without cervical cancer
TruScreen Group Ltd | NZBN 9429030105614
TRU.NZ | TRU.AX | info@truscreen.com
Suite 3.03 18-20 Orion Road, Lane Cove, NSW 2066, Australia
CE
ISO 14001
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国际药品监督管理局